1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

door Joshi, K., Muhith, A., Milner-Watts, C., Obeid, M., Khakoo, S., Bhosle, J., Minchom, A.R., O'Brien, M.
Gepubliceerd in Ann Oncol (2020)

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience

door Cui, W., Yousaf, N., Bhosle, J., Minchom, A.R., Ahmed, M., McDonald, F., Locke, I., Lee, R., O'Brien, M., Popat, S.
Gepubliceerd in Ann Oncol (2020)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

door Cui, W., Milner-Watts, C., Saith, S., Bhosle, J., Minchom, A.R., Davidson, M., Page, S., Locke, I., Yousaf, N., Popat, S., O'Brien, M.E.R.
Gepubliceerd in J Thorac Oncol (2021)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine bl...

door Minchom, A R, Saksornchai, K, Bhosle, J, Gunapala, R, Puglisi, M, Lu, S K, Nimako, K, Coward, J, Yu, K C, Bordi, P, Popat, S, O'Brien, M E R
Gepubliceerd in BMJ Open Respir Res (2014)